ストックスクリーナーアプリを入手
1.02
0.00%
0.00
アフターアワーズ：
1.00
-0.02
-1.96%
前日終値:
$1.02
開ける：
$1.01
24時間の取引高:
2.32M
Relative Volume:
0.66
時価総額：
$273.62M
収益：
$236.20M
当期純損益:
$-5.35M
株価収益率:
-56.98
EPS:
-0.0179
ネットキャッシュフロー:
$67.70M
1週間 パフォーマンス:
-3.77%
1か月 パフォーマンス:
-28.17%
6か月 パフォーマンス:
-34.19%
1年 パフォーマンス:
-63.96%
1日の値動き範囲:
$1.00
$1.05
1週間の範囲:
$0.875
$1.0886
52週間の値動き範囲:
$0.875
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.02 | 273.62M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-04-28 | 開始されました | Leerink Partners | Outperform |
| 2025-04-01 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 再開されました | BTIG Research | Buy |
| 2023-08-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-31 | ダウングレード | Needham | Buy → Hold |
| 2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 繰り返されました | Needham | Buy |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-02 | 開始されました | JP Morgan | Overweight |
| 2019-03-20 | 開始されました | Citigroup | Neutral |
| 2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 繰り返されました | Needham | Buy |
| 2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-12-19 | 開始されました | Piper Jaffray | Overweight |
| 2017-12-07 | 開始されました | BTIG Research | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | Needham | Buy |
| 2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-15 | 開始されました | Aegis Capital | Buy |
| 2016-09-29 | 開始されました | Brean Capital | Buy |
| 2016-03-16 | 繰り返されました | Needham | Buy |
| 2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
AKBA Technical Analysis & Stock Price Forecast - Intellectia AI
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Akebia plunges 20% on muted Q1 print - MSN
Number of shareholders of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Earnings call transcript: Akebia Therapeutics Q1 2026 reports EPS miss, stock falls - Investing.com Canada
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan
HC Wainwright Issues Negative Estimate for AKBA Earnings - MarketBeat
TradingKey - TradingKey
Akebia outlines phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients - MSN
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st
Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results - Yahoo Finance
Akebia Q1 2026 earnings preview - MSN
HC Wainwright Expects Lower Earnings for Akebia Therapeutics - MarketBeat
Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan - Sahm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Receives a Buy from H.C. Wainwright - The Globe and Mail
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Akebia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Akebia Therapeutics(AKBA) Stock Options Chain | Quotes & News - Moomoo
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Akebia (AKBA) Q1 2026 Earnings Transcript - AOL.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA): Is Breakeven Near? - 富途牛牛
Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript - GuruFocus
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Zacks Research - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: A Biotech with Significant Upside Potential - DirectorsTalk Interviews
Akebia Therapeutics (AKBA) Losses Narrow To US$9.1 Million Challenging Bearish Profitability Narratives - Sahm
Akebia Therapeutics (NASDAQ:AKBA) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Akebia Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Akebia Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Akebia Therapeutics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Akebia’s Q1 2026 results miss forecasts, stock drops - Investing.com Canada
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Akebia Therapeutics (NASDAQ: AKBA) swings to Q1 2026 loss amid new Auryxia generic - Stock Titan
AKBA: Vafseo growth and pipeline advances offset Auryxia declines, with cash to fund operations for two years - TradingView
Akebia Therapeutics: Q1 Earnings Snapshot - KVUE
Akebia (NASDAQ: AKBA) Q1 2026 loss amid Auryxia decline, Vafseo growth - Stock Titan
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - GlobeNewswire
MSN Money - MSN
Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Akebia Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Akebia gives 7 new hires stock options tied to 208,800 shares - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology - marketscreener.com
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
1.92%
4.44%
大文字化:
|
ボリューム (24 時間):